In the early stages of my affliction, I paid it no mind. My skin was discolored, but it wasn't painful. I let it be. A year later (2017), I noticed that my knees were reddish. Again, I paid it no mind because it wasn't painful. 6 months later, It started on my elbows. Now I was concerned. I went to a doctor, and he gave me a corticosteroid cream. I used it and I was good to go. There was still redness, but the plaque disappeared. 

As time went on, I was seeing more and more inflammation. It popped up, here and there, so I used the cortisone cream and again had some results. By 2018, the cream wasn't working any longer...at all. I went back to my doctor. He gave me dovobet ointment. Wow! I was impressed. It worked so well. Inflammation was at a near zero on my body. I used the ointment. I had to scrounge to get the money to pay for this med, in spite of it costing me $250 a tube. My doctor kept on refilling the prescription for Dovobet ointment. I kept on using it. He even sent me to a dermatologist where I started to get phototherapy. That was the only thing he did in addition to the Dovobet. in the spring of 2020, the dermatologist told me to take the summer off from the phototherapy and told me to come back in the fall. When I tried to return and make an appointment, the receptionist told me that I had not been to see him in 3 months, so I had to be referred to him again by my family doctor. To date, this dermatologist has yet to return my calls, in spite of 2 referrals from my GP. 

In recent months, I have not been able to afford the ointment, due to being unemployed (government shut down my job due to Covid). My psoriasis exploded! Hands, arms, back, legs, chest, behind the ears, in my ears, on my forehead/eyebrows, eyelids, nose and cheeks were affected. Now I am constantly scratching causing lesions on my body. Blood on the inside of my shirts and pants is a common occurrence because I can't seem to stop itching. Everywhere I go, I leave a trail of skin flakes. When I get up from the couch, get up out of the bed, get out of the car, I see tons of flakes and I wasn't even scratching! I feel so ashamed. 

Passersby stare, kids point and ask about it. I have had the experience of having being singled out at work because of the mess I leave behind, unintentionally. I am embarrassed and shattered by this disease. I feel depressed. I secretly wonder how my wife can even stand to be around me, because I can barely stand to be around me. As a result, depression is a large part of my life.

Fast forward to today, and I am working to remedy my psoriasis. There is actually a new dermatologist in the practice that my general practitioner (GP) is in. I have an appointment on the 13th and am looking forward to it, anxious for it. I am learning lots here and now have some info about what I might need or want for treatments. I am actually feeling hopeful for the first time in a long, long time. 

My commitment to you folks, is to document my journey in hopes that it may help someone else in the future. If I can do that for someone, then all my suffering will have been worth it.

Cheers!

MoonLake Immunotherapeutics have announced results of a Phase 2b study of its Tri-specific Nanobody Sonelokimab an investigational IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.

Quote:

---

MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced that full results of a Phase 2b study of its Tri-specific Nanobody® Sonelokimab were published in The Lancet. Sonelokimab is an investigational IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints. It has clinically demonstrated potential to allow better disease control in dermatology and rheumatology patients. Sonelokimab showed impressive efficacy with a favorable safety profile, and numerically outperformed active control secukinumab.

In the study, dosages up to 120 mg showed rapid and significant clinical benefit compared with placebo. In the highest dosage group, almost 6 out of 10 patients (57%) achieved total skin clearance (PASI 100 response) after 24 weeks. Rapid response was demonstrated with one of three patients already achieving almost clear skin (PASI 90 response) by week 4. Analysis of an individualized dosing scheme including off-drug periods in controlled patients revealed durable responses over one year. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab, and an overall candida rate of 7.4%. Although the highest dosage and schedule could be used for future clinical studies, additional assessment and modelling may aid in the final selection of the optimal dosage and schedule. The trial was conducted by Avillion LLP under a 2017 co-development agreement with Merck KGaA, Darmstadt, Germany.

Investigator Kristian Reich MD, PhD, Chief Scientific Officer and co-founder of MoonLake Immunotherapeutics, commented: “Sonelokimab is a remarkable Nanobody with game-changing potential in the treatment of a range of IL-17A/F-driven inflammatory diseases. This study shows very high response levels in the model disease psoriasis, with a favorable benefit-safety profile. MoonLake’s aim is to also accelerate Sonelokimab’s development in other inflammatory diseases driven by IL-17A and IL-17F like psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa. Our aim is to elevate treatment goals in these diseases based on the unique characteristics of Sonelokimab, giving patients with common and burdensome skin and joint conditions a chance of better disease control.”

Mark Weinberg, MD, MBA, co-author of the publication and Chief Medical Officer of Avillion LLP, commented: “Following completion of our Phase 2b activities with Merck KGaA, we are excited to see Solenokimab continue in development. Data on this Tri-specific Nanobody demonstrates potential in major inflammatory diseases driven by IL-17A and IL-17F. These diseases have a profound effect on patients’ lives not just physically but emotionally and socially. We’ve seen a continued evolution of biologic therapies in the last 25 years and I am looking forward to seeing further development of this novel nanobody biologic by MoonLake.”

The randomized, double-blind, placebo controlled, multi-center, Phase 2b study was designed to assess efficacy, safety and tolerability of Sonelokimab in subjects with moderate-to-severe chronic plaque-type psoriasis. The trial enrolled 313 patients (age 18-75) with chronic plaque psoriasis for at least six months, with an Investigator Global Assessment (IGA) score ≥3, involved body surface area ≥10%, and Psoriasis and Severity Index (PASI) ≥12 at screening and at baseline. Patients were randomized to one of four dose regimens of Sonelokimab, or a placebo comparator arm, or a reference arm (secukinumab).

This clinical trial significantly expands the number of patients and duration of therapy evaluated for Sonelokimab in plaque psoriasis and represents the first Phase 2 evaluation of a Nanobody® IL-17 A/F inhibitor in psoriasis. The study found Sonelokimab was efficacious in the treatment of plaque psoriasis. The safety profile reflects the mechanism of action with oral Candida as the most reported adverse event, in the same range as IL-17A inhibitors (7.4%).

MoonLake Immunotherapeutics was established by an international team of immunology specialists to accelerate the clinical development of Sonelokimab, building on robust clinical data generated by Merck KGaA, Darmstadt, Germany, and by Ablynx, a Sanofi company, which discovered the molecule.

MoonLake Immunotherapeutics plans to accelerate the development of Sonelokimab in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F. This group of IL-17A/F Inflammatory Diseases (introducing the novel concept of AFID) includes psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake Immunotherapeutics plans to initiate multiple Phase 2 trials soon.

This small study suggests more should be looked at in the role of interleukin 30 (IL-30) and psoriasis

Quote:

---

Objectives:
To examine the serum levels of interleukin (IL)-30 in patients with psoriasis and evaluate the correlations with the Psoriasis Area and Severity Index (PASI).

Methods:
Serum was collected from 26 patients with psoriasis and 26 healthy controls in a case–control setting, and the level of IL-30 was determined using an enzyme-linked immunosorbent assay. Statistical analysis of the IL-30 levels among groups and further correlation analyses of IL-30 levels with PASI scores were performed.

Results:
A significant increase in the level of IL-30 in patients with psoriasis compared with healthy controls was observed. In addition, a positive correlation between the IL-30 concentration and PASI scores was found in patients with psoriasis.

Conclusion:
IL-30 is presumably involved in the proliferation of epidermal cells during the development of psoriasis. Further studies with a larger number of participants are required to comprehensively elucidate the biological roles of IL-30 in the pathogenesis of psoriasis.

This months poll asks: Have you ever been asked if psoriasis is contagious

Members and guests can vote in the poll above, and our members are welcome to post in this thread too if they wish.

*Members usernames will not be shown.

Hi all,  I am new to the Psoriasis club but unfortunately not new to Psoriasis.  Up to now I have mostly managed my psoriasis thru topical treatments but have finally decided to try the more serious stuff as am  just not managing to keep it under control any longer, especially my scalp psoriasis which is now all over my scalp and behind and in my ears.  Am due to pick up my prescription for Skilarence today ?.   Am really nervous of the side effects especially the cramps and diarrhoea. But having read some of the experiences on the forum am feeling a bit more hopeful that I will hopefully be able to deal with them.

From what I have read taking with plenty of water and bland food is important and starting slowly.  Starting today with 1 30mg tablet. Any other recommendations.  Thanks Jean

I am new here. Up until now, I have been given dovobet ointment, with mixed results. Right now I am reading all I can to learn about different treatments so I can go to my doctor with lots of options to dovobet. Mainly I am sick and tired of ruining my furniture with the ointment, and leaving a snail trail everywhere I go. That and the itching is driving me nuts. Embarrassed about the trail of skin flakes I leave behind as well. I also live in Manitoba, Canada and was wondering about treatments and covered drugs, as I am not a rich man by any means.

Lilly have announced in their first quarter results that they will be dropping mirikizumab for psoriasis.

Quote:

---

The company announced that mirikizumab met the primary and all key secondary endpoints in a Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis.

The company announced that the development program for mirikizumab will henceforth focus on the ulcerative colitis and Crohn's disease indications.

While the OASIS program generated positive results for mirikizumab with safety and efficacy similar to other IL-23p19s, the company no longer plans to submit mirikizumab for regulatory approval in psoriasis in any geography.

UCB publish "Be Radiant" and "Be Sure" phase 3 data.

Quote:

---

BE RADIANT RESULTS
The Phase 3b BE RADIANT study compared the efficacy and safety of bimekizumab to secukinumab in adults with moderate to severe plaque psoriasis. The study met its primary endpoint, with significantly more patients treated with bimekizumab achieving complete skin clearance, as measured by a 100 percent improvement from baseline in the Psoriasis Area and Severity Index (PASI 100) at week 16, compared to those treated with secukinumab (61.7 percent versus 48.9 percent, respectively; p<0.001).
The study also met all ranked secondary endpoints.1 The superior levels of complete skin clearance observed at week 16 continued through to week 48, with 67.0 percent of patients treated with bimekizumab, achieving PASI 100, compared to 46.2 percent of patients treated with secukinumab (p<0.001). At week 48, both bimekizumab maintenance dosing groups (every four weeks [Q4W] and every eight weeks [Q8W]), showed higher rates of complete skin clearance (PASI 100), compared with secukinumab (p<0.001). In addition, at week 4, significantly more patients treated with bimekizumab achieved PASI 75 compared to patients treated with secukinumab (71.0 percent versus 47.3 percent, respectively; p<0.001).
“In BE RADIANT, patients treated with bimekizumab achieved superior levels of complete skin clearance, PASI 100, compared with secukinumab-treated patients at week 16, the primary endpoint of the study, and up to 48 weeks of therapy. At week 4, a faster onset of response was also observed with bimekizumab compared with secukinumab.  Data from this study support the value of inhibition of IL-17F in addition to IL-17A in the treatment of patients with moderate to severe plaque psoriasis.” said Prof. Kristian Reich, M.D., Ph.D., Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany.
Across the study duration, the most common treatment-emergent adverse events (TEAEs) with bimekizumab were upper respiratory tract infections* (38.9 percent), oral candidiasis (19.3 percent) and urinary tract infection (6.7 percent). Oral candidiasis cases were predominantly mild or moderate and none led to discontinuation. Over 48 weeks, the incidence of serious TEAEs was 5.9 percent with bimekizumab and 5.7 percent with secukinumab.

BE SURE RESULTS
The Phase 3 BE SURE study compared the efficacy and safety of bimekizumab to adalimumab in adults with moderate to severe plaque psoriasis. Results from the BE SURE study were previously reported at the European Academy of Dermatology and Venereology (EADV) Congress 2020.
BE SURE met its co-primary endpoints, demonstrating that bimekizumab-treated patients achieved superior levels of skin clearance, at week 16, compared to those who received adalimumab, as measured by PASI 90 and Investigator’s Global Assessment (IGA) response of clear or almost clear skin (IGA 0/1); p<0.001 for both comparisons. These results were further supported by the study meeting all ranked secondary endpoints. The safety profile of bimekizumab was consistent with earlier clinical studies with no new safety signals identified.
In September 2020, UCB announced that the FDA and EMA had accepted the Company’s Biologics License Application (BLA) and Marketing Authorization Application (MAA), respectively, for bimekizumab for the treatment of moderate to severe plaque psoriasis in adults. UCB is committed to bringing bimekizumab to patients worldwide and additional regulatory filings are underway.

About Bimekizumab
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively and directly inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently of IL-17A.Selective inhibition of IL-17F in addition to IL-17A suppresses inflammation to a greater extent than IL-17A inhibition alone. The safety and efficacy of bimekizumab are being evaluated across multiple disease states as part of a robust clinical program.

Amgen today announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease.

Quote:

---

"Many people with mild-to-moderate plaque psoriasis still report challenges in managing their symptoms, which can have a significant impact on their daily lives, despite the availability of existing topical treatment options," said Linda Stein Gold, M.D., director of dermatology clinical research at Henry Ford Health System, Detroit, and lead investigator for the ADVANCE study. "The ADVANCE findings demonstrated that oral apremilast significantly improved clinical measures of disease severity, such as Body Surface Area and scalp involvement."

In ADVANCE, oral Otezla 30 mg twice daily achieved a statistically significant improvement of the primary endpoint of static Physician's Global Assessment (sPGA) response at week 16 compared to placebo (21.6% vs. 4.1%, p<0.0001). These clinical improvements were maintained through week 32.

Otezla also demonstrated improvements in all secondary endpoints at week 16. A greater proportion of adults with BSA ≤5% treated with Otezla compared to placebo achieved a BSA ≤3% (respectively 71.7% vs. 35.8%), at least a 75% improvement in BSA (29.0% vs. 6.1%) and a Scalp PGA (ScPGA) response score of clear or almost clear (35.6% vs. 12.9%).

Comparable improvements in disease severity were seen in adults with BSA >5% in ADVANCE. At week 16, a greater proportion of adults with BSA >5% treated with Otezla compared to placebo achieved a BSA ≤3% (respectively 54.6% vs. 14.9%), at least a 75% improvement in BSA (36.8% vs. 8.6%), and a ScPGA response score of clear or almost clear (50.6% vs. 19.2%).

The adverse events observed in this trial analysis were consistent with the known safety profile of Otezla. The most commonly reported (≥5%) treatment-emergent adverse events with Otezla treatment were diarrhea (14.3%), headache (12.9%), nausea (12.7%), upper respiratory tract infection (8.5%) and nasopharyngitis (6.8%).

"These positive ADVANCE results add to the growing evidence supporting the potential benefit of Otezla in adults with mild-to-moderate plaque psoriasis," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "We look forward to continuing to work with the FDA to potentially expand access to oral Otezla to adults with mild-to-moderate disease severity."

In the U.S., Otezla is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis and for adult patients with oral ulcers associated with Behçet's Disease. Since its initial FDA approval in 2014, Otezla has been prescribed to more than 250,000 patients with moderate-to-severe plaque psoriasis or active psoriatic arthritis in the U.S.

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla (apremilast)

Quote:

---

Bristol Myers Squibb today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib. Deucravacitinib was well tolerated with a low rate of discontinuation due to adverse events (AEs).

Deucravacitinib demonstrated superior skin clearance compared with Otezla® (apremilast) for key secondary endpoints in both studies, as measured by PASI 75 and sPGA 0/1 responses at Week 16 and Week 24. Findings include:

PASI 75 Response in POETYK PSO-1 and POETYK PSO-2:

• At Week 16, 58.7% and 53.6% of patients receiving deucravacitinib achieved PASI 75 response, respectively, versus 12.7% and 9.4% receiving placebo and 35.1% and 40.2% receiving Otezla.
  
• At Week 24, 69.0% and 59.3% of patients receiving deucravacitinib achieved PASI 75 response, respectively, versus 38.1% and 37.8% receiving Otezla.
  
• Among patients who achieved PASI 75 response at Week 24 with deucravacitinib and continued treatment with deucravacitinib, 82.5% and 81.4%, respectively, maintained PASI 75 response at Week 52.
  

sPGA 0/1 Response in POETYK PSO-1 and POETYK PSO-2:

• At Week 16, 53.6% and 50.3% of patients receiving deucravacitinib achieved sPGA 0/1 response, respectively, versus 7.2% and 8.6% receiving placebo and 32.1% and 34.3% receiving Otezla.
  
• At Week 24, 58.4% and 50.4% of patients receiving deucravacitinib achieved sPGA 0/1 response, respectively, versus 31.0% and 29.5% receiving Otezla.
  

“In both pivotal studies, deucravacitinib was superior to Otezla across multiple endpoints, including measures of durability and maintenance of response, suggesting that deucravacitinib has the potential to become a new oral standard of care for patients who require systemic therapy and need a better oral option for their moderate to severe plaque psoriasis,” said April Armstrong, M.D., M.P.H., Associate Dean and Professor of Dermatology at the University of Southern California. “As many patients with moderate to severe plaque psoriasis remain undertreated or even untreated, it is also highly encouraging to see that deucravacitinib improved patient symptoms and outcomes to a greater extent than Otezla.”

Superiority of Deucravacitinib Versus Placebo and Otezla

Deucravacitinib demonstrated a robust efficacy profile, including superiority to placebo for the co-primary endpoints and to Otezla for key secondary endpoints. In addition to PASI 75 and sPGA 0/1 measures, deucravacitinib was superior to Otezla across both studies in multiple other secondary endpoints, demonstrating significant and clinically meaningful efficacy improvements in symptom burden and quality of life measures.

Deucravacitinib was well-tolerated and had a similar safety profile in both trials. At Week 16, 2.9% of 419 patients on placebo, 1.8% of 842 patients on deucravacitinib and 1.2% of 422 patients on Otezla experienced serious adverse events (SAEs) across both studies. The most common AEs (≥5%) with deucravacitinib treatment at Week 16 were nasopharyngitis and upper respiratory tract infection with low rates of headache, diarrhea and nausea. At Week 16, 3.8% of patients on placebo, 2.4% of patients on deucravacitinib and 5.2% of patients on Otezla experienced AEs leading to discontinuation. Across POETYK PSO-1 and POETYK PSO-2 over 52 weeks, SAEs when adjusted for exposure (exposure adjusted incidence per 100 patient-years [EAIR]) were 5.7 with placebo, 5.7 with deucravacitinib and 4.0 with Otezla. In the same timeframe across both studies, EAIRs for AEs leading to discontinuation were 9.4 with placebo, 4.4 with deucravacitinib and 11.6 with Otezla. No new safety signals were observed during Weeks 16‒52.

Across both Phase 3 trials, rates of malignancy, major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and serious infections were low and generally consistent across active treatment groups. No clinically meaningful changes were observed in multiple laboratory parameters (including anemia, blood cells, lipids and liver enzymes) over 52 weeks.

“The findings from both studies affirm that deucravacitinib – a first-in-class, oral, selective TYK2 inhibitor with a unique mechanism of action that inhibits the IL-12, IL-23 and Type 1 IFN pathways –may become an oral treatment of choice for people living with psoriasis. We believe deucravacitinib has significant potential across a broad range of immune-mediated diseases, and we are committed to further advancing our expansive clinical program with this agent,” said Mary Beth Harler, M.D., head of Immunology and Fibrosis Development, Bristol Myers Squibb. “We are in discussions with health authorities with the goal of bringing this new therapy to appropriate patients as soon as possible. At Bristol Myers Squibb, we are committed to building an immunology portfolio that addresses pressing unmet needs that exist for those impacted by serious dermatologic conditions and other immune-mediated diseases, to ultimately deliver the promise of living a better life.”

Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof

Quote:

---

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 (tapinarof 1%, n=340; vehicle, n=170) and PSOARING 2 (tapinarof 1%, n=343; vehicle, n=172), at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021) on April 23-25, 2021.

The posters feature important secondary efficacy endpoints and patient-reported outcomes data from patients with mild, moderate, or severe chronic plaque psoriasis after 12 weeks of treatment with tapinarof cream 1% dosed once daily (QD) compared to vehicle QD.

Endpoints reported include ≥90% reduction in Psoriasis Area and Severity Index (PASI90) (an endpoint more commonly used in assessing systemic agents), itch reduction measured with the Peak Pruritis Numerical Rating Scale (PP-NRS), and improvement in quality of life as measured by the Dermatology Life Quality Index (DLQI). All secondary endpoints were met with highly statistically significant results, and patients treated with tapinarof showed significant improvement in all measures of disease activity included in the studies.

Highlights from Secondary Efficacy Endpoints and Patient-Reported Outcomes:

• PASI90 – At Week 12, a significantly higher proportion of patients treated with tapinarof cream 1%, QD achieved PASI90 in PSOARING 1 (18.8%) and PSOARING 2 (20.9%) compared to patients treated with vehicle in PSOARING 1 (1.6%; P=0.0005) and PSOARING 2 (2.5%; P<0.0001).
  

• ≥4-point Improvement in PP-NRS – Peak Pruritis-NRS – A statistically significant higher proportion of patients treated with tapinarof cream 1%, QD achieved at least a 4-point NRS improvement – a change that is considered clinically meaningful – at each time point from Week 2 through Week 12. At Week 12 in PSOARING 1 and PSOARING 2 that proportion was 67.5% and 59.7% respectively, compared to patients treated with vehicle (46.1% in PSOARING 1; P=0.0004, and 31.3% in PSOARING 2; P<0.0001).
  

• DLQI – At Week 4, patients treated with tapinarof cream, 1% QD reported significant improvements in quality of life as measured by the DLQI. A minimal clinically important difference of –4.0 in DLQI was exceeded at Week 12 for patients treated with tapinarof (–5.0 in PSOARING 1; –4.7 in PSOARING 2). These reductions were significant (both P<0.0001) compared to vehicle (–3.0 in PSOARING 1; –1.6 in PSOARING 2).
  

“It is encouraging to see Phase 3 secondary endpoints data like this from a topical,” said Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System. “Seeing the PASI90 scores for approximately one in five patients in the PSOARING pivotal trials makes me extremely excited for what tapinarof may mean as a treatment option for patients with psoriasis, if approved.”

Eli Lilly say their Taltz (Ixekizumab) delivers more cumulative days with completely clear skin for adults with psoriasis compared to seven other biologics in novel network meta-analysis.

Quote:

---

Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's Taltz® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied.

"We are thrilled to present our novel analysis of clinical trial data showing Taltz provided numerically more cumulative days of completely clear skin for adult patients suffering from psoriasis, compared to seven other biologic options. This analysis reinforces our clinical trial findings which previously showed that Taltz provides rapid and sustained improvement of psoriasis. We're pleased to give dermatologists additional insights about Taltz that can help them make important treatment decisions for patients who seek totally clear skin," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "At Lilly, it's equally important that our research goes beyond controlled clinical trials to include real-world analyses that provide clarity for dermatologists around how patients manage their psoriasis and respond to treatment in everyday life."

In the network meta-analysis to assess the cumulative clinical benefits of biologics in psoriasis, using PASI 100 to measure the early and sustained effect of biologic medications approved for psoriasis over one year, Taltz offered patients with psoriasis the greatest number of cumulative days of completely clear skin compared to adalimumab, brodalumab, etanercept, guselkumab, risankizumab, secukinumab and ustekinumab. In this analysis, Taltz showed one to 18 more cumulative weeks of completely clear skin over one year compared to these seven other biologics.

Taltz provided patients with a total of 159 cumulative days (95% credible interval, 147.4-170.0 days), or 23 weeks of completely clear skin (PASI 100), which translates into a patient having completely clear skin for approximately 44% of the year compared to: risankizumab (152 days [141.6-162.0 days], or 22 weeks and 42% of the year); brodalumab (138 days [119.0-157.2 days], 20 weeks and 38% of the year); guselkumab (131 days, [120.8-141.6 days], 19 weeks and 36% of the year); secukinumab (119 days [111.7-127.0 days], or 17 weeks and 33% of the year); ustekinumab (74 days [63.3-84.4 days], or 11 weeks and 20% of the year), adalimumab (67 days [55.7-77.9 days], or 10 weeks and 18% of the year) and etanercept (32 days [23.7-39.7 days], or 5 weeks and 9% of the year).

People with psoriasis taking Taltz achieved greater success taking medication as prescribed (adherence) and staying on medication for the prescribed duration (persistence), without needing additional medications (monotherapy), compared to those taking secukinumab, ustekinumab, adalimumab and etanercept up to three years. Patients on Taltz stayed on treatment an observed median of nearly 22 weeks longer vs. all other biologics pooled (414 vs. 259 days, [59 vs. 37 weeks], p<0.001) and approximately 11 to 34 weeks longer vs. individual treatments: secukinumab (335 days [48 weeks]), adalimumab (301 days [43 weeks]), etanercept (181 days [26 weeks]) and ustekinumab (176 days [25 weeks]). Compared with the pooled set of other biologics where patients stayed on prescription for less than half of the year (45.7%), patients on Taltz took treatment as prescribed for over half of the year (53.2%), as measured by proportion of days covered (PDC) by prescribed treatment (p<0.001). Patients taking Taltz also experienced more time (52.7% of the year) on monotherapy compared to the pooled set of other biologics (44.8% of the year) (p<0.001).

Compared to guselkumab, patients with psoriasis on Taltz adhered to treatment for nearly eight weeks more time (Taltz: median of 272 days or 39 weeks [PDC=0.75]; guselkumab: 219 days or 31 weeks [PDC=0.60], p=0.001) and had approximately six weeks more time on monotherapy (Taltz: median of 247 days or 35 weeks [PDC=0.68]; guselkumab: 202 days or 29 weeks [PDC=0.55], p=0.002) over one year. Among those patients who required additional psoriasis therapies, the need for systemic medication was similar for patients taking Taltz or guselkumab over the year.

Among participants who had previously used a biologic, patients with psoriasis treated with Taltz were more likely to be "highly adherent," which was measured by more than 80% of days where they took treatments as prescribed (Taltz: 42.0% vs. secukinumab: 35.0%, p=0.019). Taltz was associated with 25% lower risk of switching treatments, 20% lower risk of stopping treatment before the end of the prescribed duration (non-persistence), 19% lower risk of discontinuing treatment, and 36% higher odds of taking treatment as prescribed (adherence) than secukinumab.

Following this thread Skyrizi psoriatic arthritis phase 3 results AbbVie have applied to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval to treat psoriatic arthritis.

Quote:

---

AbbVie today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI® (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis.1 The submissions were supported by two pivotal Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated SKYRIZI in adults with active psoriatic arthritis including those who had responded inadequately or were intolerant to biologic therapy and/or non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

"Most patients living with psoriatic arthritis experience both skin and joint disease which can be especially burdensome. Despite advancements, many patients cannot find relief from the signs and symptoms of this disease," said Michael Severino, M.D., vice chairman and president, AbbVie. "We are dedicated to providing options that can help more patients living with psoriatic arthritis reach their treatment goals."

In the Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, SKYRIZI demonstrated significant improvements in disease activity (as measured by ACR20 response and minimal disease activity), skin clearance (as measured by at least a 90 percent improvement in Psoriasis Area Severity Index [PASI 90]) and physical function (as measured by the Health Assessment Questionnaire Disability Index [HAQ-DI]) at week 24 versus placebo. In both studies, significantly more patients treated with SKYRIZI achieved the primary endpoint of ACR20 response at week 24 versus placebo. The safety profile of SKYRIZI in these studies was generally consistent with the safety profile of SKYRIZI in plaque psoriasis, with no new safety risks observed.

Hello Everyone,

I've had psoriasis in various degrees over the past 30+ years, and mostly been able to keep it under somewhat control with steroid cream, UVB therapy or puva baths, up to the past 10 months were its kinda getting out of control.  
I joined this group looking to see what people have had success with and just talk to people going through the same struggles.  

Treena ?

This months poll asks:  Has psoriatic arthritis affected your life

Members and guests can vote in the poll above, and our members are welcome to post in this thread too if they wish.

*Members usernames will not be shown.

I've had a search but cannot seen to find an answer.  If is possible to post a video?  There is a BB code for videos but it doesn't seem to work

"[video]"www.dummylink.com/dummy.mp4"[/video]

I am curious to know if I try some drugs (biologics etc.) for PsA and Ps and I stop them will I get a rebound flairup like I used to when I used topical steroid creams?

I have sworn off Cortisone forever and the way Dermatologists prescribe it by the tube after tube ad nauseum....I must have 8 tubes of this skin thinner and regret the way I have used way too much over the years. My wife who is a clinical Pharmacist warned me that skin damage would be the end result, but that's all they gave me by the bucket full. I now have been using the new non-Cortisonal," Tazarotene" cream at $75.00 US for 30 gram small tube, The gel of the same is over $700.00 US per tube thanks to Big Pharm. The Flesh on my elbow and knee is so thin it bleeds at will, leaving behind an angry red mess that seems to be the end of normal skin ever coming back. Thank You For This Forum and You Folks and my everlasting Rants, Best Regards...........

Johnson & Johnson release long-term data showing skin clearance, joint symptom relief, and safety of Tremfya (guselkumab)

Quote:

---

Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112). These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis and dactylitis was also seen through Week 100. In addition, the extent of radiographic progression was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021.1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S. to treat both adults with active PsA and adults with moderate to severe plaque psoriasis (PsO).

“PsA can be a chronically painful and debilitating disease, and many PsA patients are still searching for enduring relief of their symptoms,” said Philip J. Mease,e M.D., of the Swedish Medical Center/Providence St. Joseph Health and the University of Washington in Seattle, Washington and presenting author. “These data, which show that the observed benefits of TREMFYA in PsA continue through two years, represent positive news for physicians and patients alike.” 

Results showed that at Week 100:

Complete Skin Clearance: In patients who had clinically meaningful skin involvement at baseline, 59 percent of those receiving TREMFYA every four weeks and 53 percent of those receiving TREMFYA every eight weeks achieved complete skin clearance (Psoriasis Area Severity Index [PASI] 100; utilizing non-responder imputation [NRI], with this method of analysis, subjects with missing data are assumed to be non-responders).

Joint Symptom Improvement: Among randomized patients, 76 percent of those receiving TREMFYA and 74 percent of those receiving TREMFYA achieved at least 20 percent improvement in the American College of Rheumatology (ACR 20) response criteria (utilizing NRI).

Radiographic Progression: At Week 24, TREMFYA demonstrated statistically significant inhibition of radiographic progression of joint structural damage (p=0.011) (as measured by PsA-modified van der Heijde-Sharp [vdH-S scores]). TREMFYA afforded numerically, but not statistically significant, less radiographic progression (p=0.072) compared with placebo. From Week 52-100, low rates of radiographic progression of joint damage were observed in patients receiving TREMFYA (0.75) and TREMFYA (0.46), which were both further numerically reduced from the results observed during Weeks 0-52 (1.06, 0.99,). In the group of patients who crossed over from placebo to TREMFYA at Week 24, mean changes in vdH-S scores were 1.12 from Week 0-24 while receiving placebo, and 0.34 from Week 24-52 and 0.13 from Week 52-100 while receiving TREMFYA, indicating that further numerical improvements were also made through Year Two in this group.

Durability: Robust joint and skin response rates and mean improvements from baseline in outcome measures were maintained through two years, and approximately 90 percent of patients randomized to TREMFYA continued treatment with TREMFYA through Week 100.

Safety: No new safety signals were observed in the safety analysis conducted through Week 112. TREMFYA safety in patients with active PsA through two years was comparable to safety at six months and one year and generally consistent with TREMFYA safety in patients with moderate to severe plaque PsO.

In addition, results showed 56 percent of TREMFYA patients and 55 percent of TREMFYA patients achieved at least 50 percent improvement in ACR score (utilizing NRI). Among patients who had clinically meaningful PsO at baseline, 62 percent of TREMFYA 4 week patients and 55 percent of TREMFYA 8 week patients achieved complete skin clearance as measured by the Investigator Global Assessment (IGA) score of 0 (utilizing NRI).

Just a reminder that we do have this in our sign up agreement.

Quote:

---

Please note we have nothing to hide, and should you feel the need to hide your email by using a disposable Email address or a VPN/Proxy your account will probably be deleted.